Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the randomised Phase IIa EXIdavnemab ...
BioArctic AB (publ), a Swedish research-based biopharma company, announced that the first patient has been dosed with exidavnemab in the EXIST phase 2a study, in Parkinson’s disease patients.
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
A new study from the University of Oxford demonstrates how clinicians could use data to predict the risk of falls in people ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including ...
Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.